Why the study?
Does clopidogrel plus aspirin reduce the composite of cardiovascular death, MI, or stroke in patients with peripheral arterial disease compared to aspirin alone?
Does clopidogrel plus aspirin reduce the composite of cardiovascular death, MI, or stroke in patients with peripheral arterial disease compared to aspirin alone?
Answers are grounded in this paper and cite their sources.
In patients with peripheral arterial disease, adding clopidogrel to aspirin did not significantly reduce the primary composite of cardiovascular death, MI, or stroke, but did reduce MI and ischemic hospitalizations at the cost of increased minor bleeding.
AIMS: The aim of this study was to determine whether clopidogrel plus aspirin provides greater protection against major cardiovascular events than aspirin alone in patients with peripheral arterial disease (PAD). METHODS AND RESULTS: This is a post hoc analysis of the 3096 patients with symptomatic (2838) or asymptomatic (258) PAD from the CHARISMA trial. The rate of cardiovascular death, myocardial infarction (MI), or stroke (primary endpoint) was higher in patients with PAD than in those without PAD: 8.2% vs. 6.8% [hazard ratio (HR), 1.25; 95% CI 1.08, 1.44; P = 0.002]. Among the patients with PAD, the primary endpoint occurred in 7.6% in the clopidogrel plus aspirin group and 8.9% in the placebo plus aspirin group (HR, 0.85; 95% CI, 0.66-1.08; P = 0.18). In these patients, the rate of MI was lower in the dual antiplatelet arm than the aspirin alone arm: 2.3% vs. 3.7% (HR, 0.63; 95% CI, 0.42-0.96; P = 0.029), as was the rate of hospitalization for ischaemic events: 16.5% vs. 20.1% (HR, 0.81; 95% CI, 0.68-0.95; P = 0.011). The rates of severe, fatal, or moderate bleeding did not differ between the groups, whereas minor bleeding was increased with clopidogrel: 34.4% vs. 20.8% (odds ratio, 1.99; 95% CI, 1.69-2.34; P < 0.001). CONCLUSION: Dual therapy provided some benefit over aspirin alone in PAD patients for the rate of MI and the rate of hospitalization for ischaemic events, at the cost of an increase in minor bleeding.
No takes yet. Share an insight, caveat, or question.
Cacoub et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: